High rate of clinical complete response to weekly outpatient neoadjuvant chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5- fluorouracil, and bleomycin alternating with methotrexate and epirubicin

Cancer

Volumn 85, Issue 7, 1999, Pages 1430-1438

  Lin, Jin Ching ^a,b,c   Jan, Jian Sheng ^a,b   Hsu, Chen Yi ^a   Wong, Daniel Yong Kie ^a  

^a TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Chemotherapy; Neoadjuvant; Oral carcinoma; Weekly

Indexed keywords

BLEOMYCIN; CISPLATIN; EPIRUBICIN; FLUOROURACIL; METHOTREXATE;

ADULT; AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER REGRESSION; CERVICAL LYMPH NODE; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; LYMPH NODE METASTASIS; MALE; MOUTH CARCINOMA; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METHOTREXATE; MIDDLE AGED; MOUTH NEOPLASMS; PATIENT COMPLIANCE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033121114     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990401)85:7<1430::AID-CNCR2>3.0.CO;2-I     Document Type: Article

References (56)

1. Fletcher GH, Jesse RH. The place of irradiation in the management of the primary lesion in the head and neck cancer. Cancer 1977;39:862-7.
2. Kramer S, Gelber RD, Snow JB, Marcial VA, Lowrry LD, Davis LW, et al. Combined radiation therapy and surgery in management of advanced head and neck cancer: final report of study 73-03 of the Radiation Therapy Oncology Group. Head Neck Surg 1987;10:19-30.
3. Schuller DE, Metch B, Stein DW, Mattox D, McCracken JD. Preoperative chemotherapy in advanced resectable head and neck cancer: final report of the Southwest Oncology Group. Laryngoscope 1988;98:1205-11.
4. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: final report of Head and Neck Contracts Program. Cancer 1987; 60:301-11.
5. Merlano M, Benasso M, Corvo R, Rosso R, Vitale V, Blengio F, et al. Five-year update of a randomized trial of alternating radiotherapy and chemotherapy compared with radiotherapy alone in treatment of unresectable squamous cell carcinoma of the head and neck. J Natl Cancer Inst 1996;88: 583-9.
6. Paccagnella A, Orlando A, Marchiori C, Zorat PL, Cavaniglia G, Sileni C, et al. A phase III trial on initial chemotherapy in stage III or IV head and neck cancer: a study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994;86:265-72.
7. Tannock IF. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol 1989;16:83-101.
8. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: rational and clinical experience in patients with solid tumors. J Clin Oncol 1990;8:911-34.
9. Armand JP, Couteau C. Chemotherapy in head and neck cancer. Eur J Cancer 1995;31A:819-22.
10. Al-Sarraf M, Hussein M. Head and neck cancer: present status and future prospects of adjuvant chemotherapy. Cancer Invest 1995;13:41-53.
11. Fonseca E, Cruz JJ, Rodriguez CA, Gomez-Bernal A, Martin G, Sanchez P, et al. Randomized trial of neoadjuvant chemotherapy with cisplatin plus 5-fluorouracil, with or without leucovorin, in locally advanced head and neck cancer. Ann Oncol 1997;8:713-5.
12. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991;324:1685-90.
13. Merlano M, Vitale V, Rosso R, Benasso M, Corvo R, Cavallari M, et al. Treatment of advanced squamous-cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992;327:1115-21.
14. Taylor SG, Murthy AK, Vannetzel J-M, Colin P, Dray M, Caldarelli DD, et al. Randomized comparison of neoadjuvant cisplatin and fluorouracil infusion followed by radiation versus concomitant treatment in advanced head and neck cancer. J Clin Oncol 1994;12:385-95.
15. Adelstein DJ, Saxton JP, Lavertu P, Tuason L, Wood BG, Wanamaker JR, et al. A phase III randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer: preliminary results. Head Neck 1997; 19:567-75.
16. Allal AS, Bieri S, Miralbell R, Dulguerov P, Bardina A, Lehmann W, et al. Combined concomitant boost radiotherapy and chemotherapy in stage III-IV head and neck carcinomas: a comparison of toxicity and treatment results with those observed after radiotherapy alone. Ann Oncol 1997;8: 681-4.
17. Lewin F, Damber L, Jonsson H, Andersson T, Berthelsen A, Biorklund A, et al. Neoadjuvant chemotherapy with cisplatin and 5-fluorouracil in advanced squamous cell carcinoma of the head and neck: a randomized phase III study. Radiother Oncol 1997;43:23-8.
18. Mazeron J-B, Martin M, Brun B, Grimard L, Lelievre G, Vergnes L, et al. Induction chemotherapy in head and neck cancer: results of a phase III trial. Head Neck 1992;14:85-91.
19. Martin M, Hazan A, Vergnes L, Peytral C, Mazeron JJ, Senechaut JP, et al. Randomized study of 5-fluorouracil and cisplatin as neoadjuvant therapy in head and neck cancer: a preliminary report. Int J Radiat Oncol Biol Phys 1990;19: 973-5.
20. Jaulerry C, Rodriguez J, Brunin F, Jouve M, Mosseri V, Point D, et al. Induction chemotherapy in advanced head and neck tumors: results of two randomized trials. Int J Radiat Oncol Biol Phys 1992;23:483-9.
21. Rooney M, Kish J, Jacobs J, Kinzie J, Weaver A, Crissman J, et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985;55:1123-8.
22. Bernal AG, Cruz JJ, Sanchez P, Munoz A, Nieto A, Fonseca E, et al. Four-day continuous infusion of cisplatin and 5-fluorouracil in head and neck cancer. Cancer 1989;63:1927-30.
23. Lefebvre JL, Chevalier D, Lubornski B, Kirkpatrick A, Collette L, Sahmoud T. Larynx preservation in hypopharynx and lateral epilarynx cancer: preliminary results of EROTC randomized phase III trial 24891. J Natl Cancer Int 1996;88: 890-9.
24. Dreyfuss AI, Clark JR, Wright JE, Norris CM, Busse PM, Lucarini JW, et al. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 1990;112: 167-72.
25. Clark JR, Busse PM, Norris CM, Andersen JW, Dreyfuss AI, Rossi RM, et al. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for squamous cell carcinoma of the head and neck: long-term results. J Clin Oncol 1997;15:3100-10.
26. Papadimitrakopoulou VA, Dimery IW, Lee JJ, Perez C, Hong WK, Lippman SM. Cisplatin, fluorouracil, and L-leucovorin induction chemotherapy for locally advanced head and neck cancer: the M. D. Anderson Cancer Center experience. Cancer J Sci Am 1997;3:92-9.
27. Vokes EE, Weichselbaum RR, Mick R, Mick R, McEvilly J-M, Haraf DJ, et al. Favorable long-term survival following induction chemotherapy with cisplatin, fluorouracil, and leucovorin and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992;84: 877-82.
28. Vokes EE, Schilsky RL, Weichselbaum RR, Kozloff MF, Panje WR. Induction chemotherapy with cisplatin, fluorouracil, and high-dose leucovorin for locally advanced head and neck cancer: a clinical and pharmacologic analysis. J Clin Oncol 1990;8:241-7.
29. Jacobs C, Goffinet DR, Goffinet L, Kohler M, Fee WE. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer: a report from the Northern California Oncology Group. Cancer 1987;60: 1178-83.
30. Al-Kourainy K, Kish J, Ensley J, Tapazoglou E, Jacobs J, Weaver A, et al. Achievement of superior survival for histologically negative versus histologically positive clinically complete responders to cisplatin combination in patients with locally advanced head and neck cancer. Cancer 1987; 59:233-8.
31. Urba SG, Forastiere AA, Wolf GT, Esclamado RM, McLaughlin PW, Thornton AF, et al. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. J Clin Oncol 1994;12:946-53.
32. El-Sayed S, Nelson N. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region: a meta-analysis of prospective and randomized trials. J Clin Oncol 1996;14:838-47.
33. Merlano M, Corvo R, Margarino G, Benasso M, Rosso R, Sertoli MR, et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck. Cancer 1991;67:915-21.
34. Benasso M, Bonelli L, Numico G, Corvo R, Sanguineti G, Rosso R, et al. Treatment with cisplatin and fluorouracil alternating with radiation favorably affects prognosis of inoperable squamous cell carcinoma of the head and neck: results of a multivariate analysis on 273 patients. Ann Oncol 1997;8:773-9.
35. Jeremic B, Shibamoto Y, Stanisavljevic B, Milojevic L, Milicic B, Nikolic N. Radiation therapy alone or with concurrent low-dose daily either cisplatin or carboplatin in locally advanced unresectable squamous cell carcinoma of the head and neck: a prospective randomized trial. Radiother Oncol 1997;43:29-37.
36. Haffy BG, Son YH, Papac R, Sasaki CT, Weissberg JB, Fischer D, et al. Chemotherapy as an adjunct to radiation in the treatment of squamous cell carcinoma of the head and neck: results of the Yale mitomycin randomized trials. J Clin Oncol 1997;15:268-76.
37. Bachaud J-M, David J-M, Boussin G, Daly N. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 1991;20:243-6.
38. Gupta NK, Pointon RCS, Wilkinson PM. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987;38:575-81.
39. Fu KK, Philips TL, Silverberg IJ, Jacobs C, Goffinet DR, Chun C, et al. Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987;5:1410-8.
40. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of The Head and Neck Contracts Program. J Clin Oncol 1990;8:838-47.
41. Laramore GE, Scott CB, Al-Sarraf M, Haselow RE, Ervin TJ, Wheeler R, et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: report on Intergroup Study 0034. Int J Radiat Oncol Biol Phys 1992;23: 705-13.
42. Fountzilas G, Daniilidis J, Sridhar KS, Kalogera-Fountzila A, Zaramboukas T, Sombolos K, et al. Induction chemotherapy with a new regimen alternating cisplatin, fluorouracil with mitomycin, hydroxyurea and bleomycin in carcinomas of nasopharynx or other sites of the head and neck region. Cancer 1990;66:1453-60.
43. Ensley J, Kish J, Tapazoglou E, Jacobs J, Weaver A, Atkinson D, et al. An intensive, five course, alternating combination chemotherapy induction regimen used in patients with advanced, unresectable head and neck cancer. J Clin Oncol 1988;6:1147-53.
44. Munro AJ. An overview of randomized controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer 1995;71:83-91.
45. Jacobs C, Pinto H. Adjuvant and neoadjuvant treatment of head and neck cancers: the next chapter. Semin Oncol 1995; 22:540-52.
46. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
47. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. American Joint Committee on Cancer: manual for staging of cancer. 4th edition. Philadelphia: J.B. Lippincott, 1992.
48. Withers HR, Taylor JM, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988;27:131-46.
49. Harari PM. Why has induction chemotherapy for advanced head and neck cancer become a United States community standard of practice? J Clin Oncol 1997;15:2050-5.
50. Aukerman SL, Fidler IJ. The heterogeneous nature of metastatic neoplasms: relevance to biotherapy. In: Oldman RK, editor. Principles of cancer therapy. New York: Raven Press, 1987:21-47.
51. Dexter DL, Calabresi P. Intraneoplastic diversity. Biochim Biophys Acta 1982;695:97-112.
52. Fidler IJ, Kripke ML. Metastasis results from preexisting variant cells within a malignant tumor. Science 1977;197: 893-5.
53. Mitelman F, Mark J, Levan G, Levan A. Tumor etiology and chromosomal pattern. Science 1972;176:1340-1.
54. Byers VS, Hohnston JO. Antigenic differences among osteogenic sarcoma tumor cells taken from different locations in human tumors. Cancer Res 1977;37:3173-83.
55. Barranco SC, Drewinko B, Humphrey RM. Differential response by human melanoma cells to 1,3-bis-(2-chloroethy)-1-nitrosourea and bleomycin. Mutat Res 1973;19: 277-80.
56. Richardson ME, Siemann DW. Tumor cell heterogeneity: impact on mechanisms of therapeutic drug resistance. Int J Radiat Oncol Biol Phys 1997;39:789-95.